Richard Law

Outlook Amazon AWS Mobile Friendly Google Font API Google Tag Manager Viewpoint

lncrna genomic medicines fibrosis biotechnology research precision medicine rna therapies dark genome long non-coding rnas disease reprogramming therapeutic target discovery oncology treatments fibrosis treatment cancer immunotherapy cardiovascular therapies anti-fibrotic therapies drug development clinical trials therapeutics for chronic diseases diagnostic platforms cell-specific treatments multifactorial disease targeting computation biology biotechnology lncrna feature discovery environmental signal integration disease modifying therapy rna-guided therapeutics regulatory genome tumor microenvironment clinical candidate selection biomarkers oncology pipeline contract research translational studies genome modulation technologies proprietary tools multi-omic data analysis biopharma partnerships therapeutic innovation medical advisory boards disease associated gene pathways rna-targeting modalities precision therapeutics clinical research sustainable growth biotech funding rna-based diagnostics antisenese oligonucleotide technology innovative drug candidates dark matter of the genome cell state catalogue therapeutic pipeline research collaborations biopharmaceutical innovative therapies disease-modifying therapeutics lncrnas heart failure fibrotic diseases chronic diseases metabolic disorders obesity antisense oligonucleotides tissue-selective therapies cell-state reprogramming collaborative research eli lilly partnership genetic medicine unmet medical needs advanced therapeutics pre-clinical development healthcare innovation switzerland u.s. operations strategic partnerships health care health wellness & fitness hospital & health care